Advertisement

CHEST Physician

Make CHEST Physician® a trusted source
  • FDA proposal would eliminate addicting power of cigarettes, other combustible tobacco products

    FDA proposal would eliminate addicting power of cigarettes, other combustible tobacco products

    While the rule could reduce smoking rates, Sven-Eric Jordt, PhD, said clinicians must remember that low-nicotine cigarettes still expose those who smoke to carcinogens.


  • Intersection of American Heart Month and Black History Month offers chance to highlight disparities in care

    Intersection of American Heart Month and Black History Month offers chance to highlight disparities in care

    Marcus St. John, MD, said health system-wide checklists can combat implicit bias and help ensure all patients receive appropriate care.


  • Key points of the 2025 Medicare Physician Fee Schedule

    Key points of the 2025 Medicare Physician Fee Schedule

    CMS has released the 2025 Medicare Physician Fee Schedule rule. Read a summary of key points that clinicians need to know about.



  • The Medicare conversion factor: What is it and why is it punishing physicians?

    The Medicare conversion factor: What is it and why is it punishing physicians?

    This year’s final rule from CMS provided the long-expected but unwelcome news of a 2.8% cut in the 2025 Medicare conversion factor.


  • Managing central airway obstruction

    Managing central airway obstruction

    New guidelines on central airway obstruction standardize diagnosis and management recommendations, emphasizing therapeutic bronchoscopy, rigid bronchoscopy, and multidisciplinary care.


  • The rising use of ketamine for airway management

    The rising use of ketamine for airway management

    Ketamine’s unique properties make it valuable for critical care treatments including airway management, sedation, and analgesia.


  • Top reads from the CHEST journal portfolio – February 2025

    Top reads from the CHEST journal portfolio – February 2025

    Read commentary of studies on oronasal CPAP for OSA, the impact of pirfenidone on IPF, and extracorporeal membrane oxygenation for high-risk PE.


  • FDA grants clearance for SIMEOX 200 for patients with chronic lung disease

    FDA grants clearance for SIMEOX 200 for patients with chronic lung disease

    The approval offers providers an alternative to traditional airway clearance therapies for patients with chronic lung diseases such as bronchiectasis, COPD, and cystic fibrosis.



  • Updated GOLD report includes significant clinical implications for COPD management

    Updated GOLD report includes significant clinical implications for COPD management

    Gerard J. Criner, MD, FCCP, a member of the GOLD science committee, said one notable change was the adoption of race-neutral algorithms and equations in predictive values for lung function testing and measuring lung impairment.


  • Consequences of wildfire smoke exposure extend beyond local area

    Consequences of wildfire smoke exposure extend beyond local area

    In a recent study, Mary E. Maldarelli, MD, and colleagues demonstrated that wildfires can increase health risks even from thousands of miles away.